-transparent.png){kind=logo}
The role of urogenical infection in males in present-day urology is demonstrated with a focus on fluoroquinolones efficacy in combined treatment of urogenital infection. The mechanism of action, pharmacokinetics, the spectrum of antimicrobial activity of a novel fluoroquinolone drug avelox are detailed. Avelox use in combined therapy of mono- and mixed infections caused by ureaplasmas, chlamidias, mycoplasms is illustrated by original experience of the authors. Avelox is well tolerated and safe.
Related Publications
I A Aboian, and
S V Pavlov, and
V I Miroshnichenko, and
A N Shestel'
January 1979,
Sexually transmitted diseases,
I A Aboian, and
S V Pavlov, and
V I Miroshnichenko, and
A N Shestel'
December 1993,
Annals of internal medicine,
I A Aboian, and
S V Pavlov, and
V I Miroshnichenko, and
A N Shestel'
October 1961,
The Journal of urology,
I A Aboian, and
S V Pavlov, and
V I Miroshnichenko, and
A N Shestel'
April 1987,
The American journal of medicine,
I A Aboian, and
S V Pavlov, and
V I Miroshnichenko, and
A N Shestel'
February 2017,
Sexually transmitted diseases,
I A Aboian, and
S V Pavlov, and
V I Miroshnichenko, and
A N Shestel'
October 2016,
Sexually transmitted diseases,
I A Aboian, and
S V Pavlov, and
V I Miroshnichenko, and
A N Shestel'
January 1997,
Sexually transmitted diseases,
I A Aboian, and
S V Pavlov, and
V I Miroshnichenko, and
A N Shestel'
November 1977,
Journal of clinical microbiology,
I A Aboian, and
S V Pavlov, and
V I Miroshnichenko, and
A N Shestel'
January 2001,
The Journal of infectious diseases,
I A Aboian, and
S V Pavlov, and
V I Miroshnichenko, and
A N Shestel'
November 1954,
Journal of the Medical Association of Georgia,
